查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1933892

按产品类型、技术、样本类型、最终用户和应用分類的即时血液检测产品市场—全球预测，2026-2032年

Point of Care Blood Testing Product Market by Product Type, Technology, Sample Type, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，照护现场血液检测产品市场规模将达到 198.2 亿美元，到 2026 年将成长至 212.9 亿美元，复合年增长率为 8.24%，到 2032 年将达到 345.1 亿美元。

关键市场统计数据
基准年 2025 198.2亿美元
预计年份：2026年 212.9亿美元
预测年份 2032 345.1亿美元
复合年增长率 (%) 8.24%

本文简要概述了分散式诊断以及影响照护现场血液检测普及的关键临床、技术和营运趋势。

照护现场血液检测正在迅速改变临床工作流程，使诊断不再局限于传统检查室，并能在各种医疗环境中加快临床决策。本报告首先概述了当前形势，说明了设备小型化、互联互通和监管协调如何降低了从急诊到居家照护等各个领域的应用门槛。引言部分为製造商、医疗系统和医保报销相关人员最为关注的技术和应用案例构建了框架，并明确了构成后续分析基础的核心术语和设备类别。

技术创新、不断变化的法规以及以价值为导向的医疗模式正在从根本上重新定义施行地点。

照护现场血液检测领域正经历着变革性的转变，这主要得益于技术创新、法规的不断改进以及医疗服务模式的转变。分子诊断和免疫检测灵敏度的提高，拓展了可在床边可靠检测的分析物范围；同时，电化学和光学感测器技术的进步降低了检测的复杂性和成本。这些创新使得以往需要中心检查室才能完成的疾病检测成为可能，有助于在各种医疗环境中更快地做出临床决策、进行分诊和治疗。

针对美国不断增加的关税压力对诊断零件和组件的影响，製造业、采购和购买环节的营运和战略应对措施

2025年美国关税政策的实施推高了照护现场血液检测所需某些零件和成品设备的投入成本，促使製造商和经销商重新评估其采购和定价策略。供应链管理人员已采取应对措施，包括供应商多元化、增加本地库存缓衝以及加快关键零件的近岸外包，以降低进口关税风险。这些营运调整对前置作业时间和采购复杂性产生了显着影响，尤其对于那些依赖专用试剂和精密设计的感测器组件的设备而言更是如此。

透过对产品分类、临床环境、临床应用、平台技术和检体类型进行详细的細項分析，确定产品推广驱动因素和发展重点。

细分市场分析揭示了临床需求、技术能力和商业性机会在产品类型、最终用户、应用、技术和检体类型方面的契合点。产品层面的差异化主要体现在检测方式：血液气体分析、心臟标记、血液凝固检验、血糖监测、血红素/血液学、传染病检查。血液凝固检验进一步细分为APTT、D-二聚体和PT/INR检测，而传染病检查则涵盖COVID-19、肝炎、HIV和流感。能够在护理点进行多种互补检测的设备，透过减少检体处理和缩短诊断时间，确保了其显着的临床效用。最终用户涵盖门诊中心、诊断检查室、居家医疗机构、医院和诊所，每种机构的采用驱动因素各不相同，包括检测量和结果週转时间、人员配备和报销问题等。医院优先考虑设备的稳定性和整合性，而居家医疗机构则更注重易用性和连接性。

区域比较：医疗保健系统和法规环境的差异如何影响采纳路径和打入市场策略

区域分析表明，医疗基础设施、法规结构和推广路径的差异正在影响照护现场血液检测的普及。美洲地区在急诊和基层医疗机构中正迅速普及即时血液检测，这得益于其整合的医疗网络和奖励缩短住院时间和改善慢性病管理的报销体系。同时，欧洲、中东和非洲的情况则更为复杂。在这些地区，监管协调正在加速部分国家的普及，而资源匮乏的国家则更需要成本更低、功能更强大的平台和分散式检查策略。此外，亚太地区正经历着用于提升诊断能力的公私投资快速增长，这主要受目标疾病高发生率以及政府为扩大偏远和都市化地区检测覆盖范围而采取的倡议的推动。

竞争格局分析强调临床检验、互通性和策略合作伙伴关係是照护现场设备製造商的关键差异化因素。

照护现场血液检测领域的竞争格局由成熟的诊断设备製造商、专业设备创新者和寻求占据特定临床适应症的新兴技术参与企业组成。拥有深厚的临床检验、丰富的监管经验和规模化生产能力的公司在医院和检查室管道保持优势，而规模较小、小规模灵活的公司则往往在用户界面设计、试剂化学和分子检测小型化方面引领创新。策略差异化越来越依赖将设备整合到临床工作流程中的能力，这需要透过软体、连接性和决策支援功能，为临床医生提供超越原始数据分析效能的实际价值。

为开发人员和商业领导者提供切实可行的策略蓝图，以加速临床应用、降低供应风险并确保永续的竞争优势。

产业领导者应采取协作策略，协调产品设计、法规事务和通路开发，以加速目标临床机构的推广应用。优先采用平台化方法，实现模组化检测扩展，初期优先推出凝血监测亚型和主要传染病检查等高影响力检测，随后利用同一硬体生态系分阶段推出其他检测项目。同时，应投资改善使用者体验和连接解决方案，确保与临床工作流程和电子健康记录 (EHR) 无缝集成，并降低临床医生采用的障碍。

我们采用了一种综合性的混合方法研究设计，结合了与主要相关人员的直接对话、二手证据的综合以及情景建模，以检验我们的实际结论。

本研究采用混合方法，结合定性一手资料收集和量化资料整合，以建立可靠的实证理解。一手研究包括对临床医生、检查室管理人员、采购负责人和监管专家进行结构化访谈，以了解医疗保健机构中实际面临的挑战和推动技术应用的因素。系统地回顾了二手资料，以了解技术趋势、监管更新和公共卫生因素的背景，并透过与一手研究结果的三角验证，检验了新出现的主题。

一份简明扼要的综述，重点阐述了实现分散式血液诊断变革潜力的临床、营运和策略要务。

照护现场血液检测正处于转折点，技术进步、不断演进的医疗模式和不断变化的监管环境正在汇聚，为改善患者疗效和提升营运效率创造了切实机会。最成功的方案将结合严格的临床检验、以使用者为中心的设计、完善的品质体係以及灵活的商业模式，以满足包括医院、门诊中心、检查室和居家医疗机构在内的各个场所的独特需求。监管合规性和供应链韧性同样重要，尤其是在地缘政治和关税相关的不确定性影响组件采购和定价的时期。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的即时血液检测产品市场

  • 血气分析
  • 心臟标记物
  • 血液凝固检验
    • APTT 试验
    • D-二聚体检测
    • PT INR 检测
  • 血糖监测
  • 血红素和血液学
  • 传染病检查
    • 新型冠状病毒感染疾病（COVID-19）
    • 肝炎
    • HIV
    • 流感

9. 按技术分類的即时血液检测产品市场

  • 电化学
  • 免疫检测
  • 分子诊断
  • 光学

10. 依检体类型分類的即时血液检测产品市场

  • 微血管血
  • 电浆
  • 血清
  • 静脉血
  • 全血

第十一章：以最终用户分類的即时血液检测产品市场

  • 门诊治疗中心
  • 诊断检查室
  • 居家医疗环境
  • 医院
  • 医生诊所

第十二章：按应用分類的即时血液检测产品市场

  • 心电图监测
  • 凝血监测
  • 重症监护
  • 糖尿病监测
  • 感染疾病诊断

13. 按地区分類的即时血液检测产品市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 依组别分類的即时血液检测产品市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国即时血液检测产品市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国即时血液检测产品市场

第十七章：中国即时血液检测产品市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abaxis
  • Abbott Laboratories
  • Accriva Diagnostics
  • ACON Laboratories
  • ARKRAY, Inc.
  • Beckman Coulter
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Bio-Rad Laboratories
  • Chembio Diagnostics
  • Danaher Corporation
  • EKF Diagnostics Holdings plc
  • HemoCue
  • Instrumentation Laboratory
  • Meridian Bioscience
  • Nova Biomedical Corporation
  • Ortho Clinical Diagnostics
  • PTS Diagnostics
  • QuidelOrtho Corporation
  • Roche Diagnostics International AG
  • Sekisui Diagnostics
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific
  • Trinity Biotech
  • Werfen
Product Code: MRR-C36616F699AA

The Point of Care Blood Testing Product Market was valued at USD 19.82 billion in 2025 and is projected to grow to USD 21.29 billion in 2026, with a CAGR of 8.24%, reaching USD 34.51 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 19.82 billion
Estimated Year [2026] USD 21.29 billion
Forecast Year [2032] USD 34.51 billion
CAGR (%) 8.24%

A concise orientation to decentralized diagnostics and the defining clinical, technological, and operational trends that shape point-of-care blood testing adoption

Point-of-care blood testing is rapidly reshaping clinical workflows, extending diagnostics beyond traditional laboratories and enabling faster clinical decision-making across diverse care settings. This report opens with an orientation to the current landscape, emphasizing how device miniaturization, connectivity, and regulatory harmonization have collectively reduced barriers to deployment in settings ranging from emergency departments to home-based care. The introduction frames the technologies and use cases that are most consequential for manufacturers, health systems, and reimbursement stakeholders, while clarifying core terminology and device classes that underpin subsequent analysis.

The narrative situates point-of-care blood testing within the broader trend toward decentralized and patient-centric care. It highlights how clinical priorities-such as reducing time to diagnosis for infectious diseases, optimizing anticoagulation management through coagulation monitoring, and enabling real-time glucose and cardiac marker measurement-drive procurement and adoption decisions. Furthermore, the introduction underscores the role of interoperability, quality assurance, and clinician training in determining how quickly and effectively point-of-care tools integrate into established clinical pathways, setting the stage for deeper examination of market dynamics and strategic implications in later sections.

How technological innovation, regulatory evolution, and value-based care models are fundamentally redefining where and how blood diagnostics are performed

The landscape for point-of-care blood testing is undergoing transformative shifts driven by technological innovation, regulatory evolution, and changing care delivery models. Advances in molecular diagnostics and immunoassay sensitivity have expanded the range of analytes that can be reliably measured at the bedside, while improvements in electrochemical and optical sensor technology have lowered per-test complexity and cost. These innovations enable accurate testing for conditions that previously required centralized laboratories, thereby accelerating clinical decision-making and enabling triage and treatment in diverse settings.

Concurrently, regulatory pathways in many jurisdictions are adapting to accommodate rapid diagnostic technologies, with a focus on post-market surveillance and quality controls that maintain clinical standards while reducing time to market. The shift toward value-based care and bundled payment models incentivizes shorter hospital stays and outpatient management, underscoring the need for point-of-care tests that deliver actionable results quickly. Integration with electronic health records and cloud-based analytics is enhancing data continuity and enabling remote monitoring, which supports chronic disease management and population health initiatives. Taken together, these shifts are redefining where diagnostics occur, who performs them, and how results inform both immediate and longitudinal clinical decisions.

Operational and strategic responses across manufacturing, sourcing, and procurement to elevated United States tariff pressures affecting diagnostic components and assemblies

The tariff environment in the United States in 2025 introduced elevated input costs for certain components and finished devices used in point-of-care blood testing, prompting manufacturers and distributors to reassess sourcing and pricing strategies. Supply chain managers responded by diversifying supplier bases, increasing local inventory buffers, and accelerating nearshoring initiatives for critical components to mitigate exposure to import duties. These operational shifts had measurable downstream effects on production lead times and procurement complexity, particularly for devices that rely on specialized reagents and precision-engineered sensor components.

In response, manufacturers prioritized design-for-manufacture approaches that reduced dependence on tariff-sensitive subsystems, while commercial teams adjusted contract structures to absorb or pass through additional costs in ways that preserved adoption momentum among health systems and ambulatory care providers. Strategic partnerships and long-term supply agreements emerged as mechanisms for stabilizing unit economics and minimizing price volatility. From a clinical standpoint, buyers emphasized total cost of ownership and reliability over headline device pricing, which influenced procurement decisions in hospitals, diagnostic laboratories, and decentralized care environments. These dynamics are likely to persist as stakeholders balance cost containment with the clinical imperative for rapid, reliable point-of-care testing.

In-depth segmentation intelligence linking product classes, care settings, clinical applications, enabling technologies, and sample modalities to reveal adoption levers and development priorities

Segmentation insights reveal where clinical needs align with technological capabilities and commercial opportunity across product types, end users, applications, technologies, and sample types. Product-level differentiation centers on modalities such as Blood Gas Analysis, Cardiac Markers, Coagulation Testing, Glucose Monitoring, Hemoglobin Hematology, and Infectious Disease Testing, with coagulation further subdivided into APTT testing, D dimer testing, and PT INR testing and infectious disease assays covering Covid-19, Hepatitis, HIV, and Influenza; devices that can perform multiple complementary assays at the point of care secure distinct clinical utility by reducing sample handling and accelerating decision timelines. End users span Ambulatory Care Centers, Diagnostic Laboratories, Home Care Settings, Hospitals, and Physicians Offices, each exhibiting different adoption drivers ranging from throughput and turnaround time to staffing and reimbursement concerns; hospitals prioritize robustness and integration, while home care settings emphasize ease of use and connectivity.

Applications cluster around Cardiac Monitoring, Coagulation Monitoring, Critical Care, Diabetes Monitoring, and Infectious Disease Diagnosis, with the highest clinical urgency found where rapid intervention changes patient outcomes. Technologies such as Electrochemical sensors, Immunoassay platforms, Molecular Diagnostics, and Optical detection shape assay sensitivity, specificity, and portability, and therefore influence which applications can realistically migrate to the point of care. Sample type considerations-Capillary Blood, Plasma, Serum, Venous Blood, and Whole Blood-determine pre-analytical workflows and user training requirements; capillary and whole blood testing favor decentralized use but require rigorous quality assurance to ensure clinical concordance with laboratory standards. Cross-segmentation analysis highlights that successful offerings combine an appropriate technology for the intended analyte, a user-centric interface for the target end user, and validated workflows for the chosen sample type to achieve adoption at scale.

Comparative regional dynamics showing how divergent healthcare systems and regulatory environments influence adoption pathways and go-to-market strategies

Regional insights reflect differing healthcare infrastructures, regulatory frameworks, and adoption pathways that shape how point-of-care blood testing is deployed. The Americas continue to emphasize rapid adoption in both acute care and primary care settings, supported by integrated health networks and reimbursement mechanisms that reward reduced length of stay and improved chronic disease management. In contrast, Europe, Middle East & Africa present a heterogeneous picture where regulatory harmonization in some countries accelerates adoption while resource constraints in others concentrate demand for low-cost, ruggedized platforms and decentralized testing strategies. Meanwhile, Asia-Pacific demonstrates strong growth in private and public investments for diagnostic capacity, driven by high prevalence of target conditions and government initiatives to expand access to testing in remote and urbanizing populations.

Across regions, differences in supply chain configurations and local manufacturing capabilities influence procurement timelines and pricing. Interoperability expectations and digital health infrastructure maturity also vary, which affects the extent to which data integration and remote monitoring features are realized. Stakeholders operating across these geographies must therefore tailor go-to-market approaches to align with local reimbursement models, regulatory requirements, and clinical practice patterns while leveraging scalable technology architectures that accommodate regional customization and global quality standards.

Competitive landscape analysis emphasizing clinical validation, interoperability, and strategic partnerships as decisive differentiators for point-of-care device makers

Competitive dynamics in point-of-care blood testing are shaped by a mix of established diagnostic manufacturers, specialist device innovators, and emerging technology entrants seeking to capture niche clinical indications. Companies that combine deep clinical validation, regulatory experience, and manufacturing scale maintain advantages in hospital and laboratory channels, while smaller, agile firms frequently drive innovation in user interface design, reagent chemistry, and molecular assay miniaturization. Strategic differentiation increasingly rests on the ability to integrate devices into clinical workflows through software, connectivity, and decision-support features that deliver clear clinician value beyond raw analytical performance.

Partnerships and alliances between device makers, reagent suppliers, and software developers are becoming more prevalent as firms seek to offer turnkey solutions that address the full testing pathway from sample collection to result interpretation and data management. Intellectual property around sensor technology and assay chemistries remains a critical barrier to entry for late-stage analytes, while nimble companies with strong reimbursement strategies and targeted clinical evidence can capture early-adopter segments. Additionally, manufacturers with robust post-market surveillance and quality systems secure trust among institutional buyers, who increasingly demand longitudinal performance data and clear lifecycle management plans for point-of-care platforms.

Actionable strategic blueprint for developers and commercial leaders to accelerate clinical adoption, mitigate supply risks, and secure sustainable competitive advantage

Industry leaders should pursue a coordinated strategy that aligns product design, regulatory engagement, and channel development to accelerate adoption across targeted care settings. Prioritize platform approaches that enable modular assay expansion, permitting an initial commercial entry with high-impact tests-such as coagulation monitoring subtypes or key infectious disease assays-followed by a staged rollout of additional analytes that leverage the same hardware ecosystem. Simultaneously, invest in user experience refinements and connectivity solutions to ensure seamless integration into clinical workflows and electronic health records, thereby reducing barriers to clinician adoption.

Operationally, diversify supply chains and consider nearshoring critical component production to mitigate tariff exposure and reduce lead-time volatility. Strengthen partnerships with clinical networks and key opinion leaders to generate pragmatic, peer-reviewed evidence that demonstrates real-world clinical utility and cost-effectiveness. Finally, tailor market entry strategies to specific end users by aligning pricing and support models with the procurement realities of hospitals, ambulatory centers, diagnostic laboratories, and home care providers, and ensure training and quality control resources are available to sustain long-term utilization and trust.

Comprehensive mixed-methods research design combining primary stakeholder engagement, secondary evidence synthesis, and scenario modeling to validate actionable conclusions

This research employed a mixed-methods approach that combined primary qualitative engagement with quantitative data synthesis to ensure robust, evidence-based findings. Primary research included structured interviews with clinicians, laboratory directors, procurement leads, and regulatory experts to capture real-world operational challenges and adoption drivers across care settings. Secondary sources were systematically reviewed to contextualize technological trends, regulatory updates, and public health drivers, and were triangulated with primary inputs to validate emerging themes.

Analytical methods encompassed cross-segmentation mapping to align product attributes with end-user needs, scenario analysis to assess impacts of policy and tariff changes on sourcing strategies, and technology readiness assessments that evaluated assay performance, manufacturability, and integration potential. Data quality was reinforced through respondent verification, expert panel reviews, and iterative synthesis to ensure that conclusions reflect both empirical evidence and practical stakeholder perspectives. Ethical considerations and data governance standards guided the treatment of proprietary inputs and ensured that analytical outputs remain actionable for commercial and clinical decision-makers.

Concise synthesis highlighting clinical, operational, and strategic imperatives for realizing the transformative potential of decentralized blood diagnostics

Point-of-care blood testing stands at an inflection point where converging technological advances, evolving care models, and shifting regulatory landscapes create tangible opportunities to improve patient outcomes and operational efficiency. The most successful initiatives will be those that marry rigorous clinical validation with user-centric design, robust quality systems, and flexible commercial models that address the distinct needs of hospitals, ambulatory centers, laboratories, and home care settings. Regulatory navigation and supply chain resilience are equally critical, particularly in the context of geopolitical and tariff-driven uncertainties that affect component sourcing and pricing.

As stakeholders evaluate investment and partnership opportunities, they should prioritize solutions that demonstrate clear clinical utility, interoperability, and total cost implications within real-world care pathways. By focusing on modular platforms, targeted assay portfolios, and scalable distribution strategies, manufacturers and health systems can accelerate deployment while maintaining the quality and reliability that clinicians expect. The cumulative effect will be a more distributed diagnostic ecosystem that supports faster clinical decisions, better chronic disease management, and more resilient healthcare delivery models.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Point of Care Blood Testing Product Market, by Product Type

  • 8.1. Blood Gas Analysis
  • 8.2. Cardiac Markers
  • 8.3. Coagulation Testing
    • 8.3.1. APTT Testing
    • 8.3.2. D Dimer Testing
    • 8.3.3. PT INR Testing
  • 8.4. Glucose Monitoring
  • 8.5. Hemoglobin Hematology
  • 8.6. Infectious Disease Testing
    • 8.6.1. Covid-19
    • 8.6.2. Hepatitis
    • 8.6.3. HIV
    • 8.6.4. Influenza

9. Point of Care Blood Testing Product Market, by Technology

  • 9.1. Electrochemical
  • 9.2. Immunoassay
  • 9.3. Molecular Diagnostics
  • 9.4. Optical

10. Point of Care Blood Testing Product Market, by Sample Type

  • 10.1. Capillary Blood
  • 10.2. Plasma
  • 10.3. Serum
  • 10.4. Venous Blood
  • 10.5. Whole Blood

11. Point of Care Blood Testing Product Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Diagnostic Laboratories
  • 11.3. Home Care Settings
  • 11.4. Hospitals
  • 11.5. Physicians Offices

12. Point of Care Blood Testing Product Market, by Application

  • 12.1. Cardiac Monitoring
  • 12.2. Coagulation Monitoring
  • 12.3. Critical Care
  • 12.4. Diabetes Monitoring
  • 12.5. Infectious Disease Diagnosis

13. Point of Care Blood Testing Product Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Point of Care Blood Testing Product Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Point of Care Blood Testing Product Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Point of Care Blood Testing Product Market

17. China Point of Care Blood Testing Product Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abaxis
  • 18.6. Abbott Laboratories
  • 18.7. Accriva Diagnostics
  • 18.8. ACON Laboratories
  • 18.9. ARKRAY, Inc.
  • 18.10. Beckman Coulter
  • 18.11. Becton, Dickinson and Company
  • 18.12. bioMerieux SA
  • 18.13. Bio-Rad Laboratories
  • 18.14. Chembio Diagnostics
  • 18.15. Danaher Corporation
  • 18.16. EKF Diagnostics Holdings plc
  • 18.17. HemoCue
  • 18.18. Instrumentation Laboratory
  • 18.19. Meridian Bioscience
  • 18.20. Nova Biomedical Corporation
  • 18.21. Ortho Clinical Diagnostics
  • 18.22. PTS Diagnostics
  • 18.23. QuidelOrtho Corporation
  • 18.24. Roche Diagnostics International AG
  • 18.25. Sekisui Diagnostics
  • 18.26. Siemens Healthineers AG
  • 18.27. Sysmex Corporation
  • 18.28. Thermo Fisher Scientific
  • 18.29. Trinity Biotech
  • 18.30. Werfen

LIST OF FIGURES

  • FIGURE 1. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY BLOOD GAS ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY BLOOD GAS ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY BLOOD GAS ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CARDIAC MARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CARDIAC MARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CARDIAC MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APTT TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APTT TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APTT TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY D DIMER TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY D DIMER TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY D DIMER TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PT INR TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PT INR TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PT INR TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY GLUCOSE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY GLUCOSE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY GLUCOSE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HEMOGLOBIN HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HEMOGLOBIN HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HEMOGLOBIN HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COVID-19, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COVID-19, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COVID-19, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HEPATITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HIV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HIV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HIV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY ELECTROCHEMICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY ELECTROCHEMICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY ELECTROCHEMICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY OPTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY OPTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY OPTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CAPILLARY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CAPILLARY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CAPILLARY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY VENOUS BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY VENOUS BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY VENOUS BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PHYSICIANS OFFICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PHYSICIANS OFFICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PHYSICIANS OFFICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CARDIAC MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CARDIAC MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CARDIAC MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CRITICAL CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CRITICAL CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY CRITICAL CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY DIABETES MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY DIABETES MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY DIABETES MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. GCC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GCC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. GCC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 182. GCC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 183. GCC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. GCC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. GCC POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. G7 POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. G7 POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. G7 POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 206. G7 POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 207. G7 POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. G7 POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. G7 POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. NATO POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. NATO POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. NATO POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 214. NATO POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 215. NATO POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. NATO POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. NATO POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. NATO POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY COAGULATION TESTING, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY INFECTIOUS DISEASE TESTING, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA POINT OF CARE BLOOD TESTING PRODUCT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)